{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:26:08Z","timestamp":1792070768615,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,13]]},"DOI":"10.7759\/cureus.90021","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T21:55:05Z","timestamp":1755122105000},"source":"Crossref","is-referenced-by-count":7,"title":["Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Ricardo Flaminio","family":"Rojas Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lynett Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Camila","family":"Amaya Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paula","family":"Saavedra Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Alopecias","author":"Rudnicka L","year":"2025","unstructured":"Rudnicka L, Stefanato CM. Alopecias. Dermatology, 5th Edition. Bolognia JL, Schaffer JV, Cerroni L (ed): Elsevier, Philadelphia; 2025. 1151-71."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjnph-2023-000733","article-title":"Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control","volume":"6","author":"Shand JA","year":"2023","unstructured":"Shand JA, Young S, Verster F, Peters C. Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control. BMJ Nutr Prev Health. 2023, 6:341-6. 10.1136\/bmjnph-2023-000733","journal-title":"BMJ Nutr Prev Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study","volume":"92","author":"Burke O","year":"2025","unstructured":"Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. J Am Acad Dermatol. 2025, 92:1141-3. 10.1016\/j.jaad.2025.01.046","journal-title":"J Am Acad Dermatol"},{"key":"ref4","article-title":"Pharmacologic treatment of overweight and obesity in adults","author":"Tchang BG","year":"2000","unstructured":"Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic treatment of overweight and obesity in adults. Endotext [Internet]. MDText.com, Inc., South Dartmouth; 2000."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez JJ","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al.. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022, 12:10.3390\/jcm12010145","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey H","year":"2025","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025, 39:e153-4. 10.1111\/jdv.20197","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins JP","year":"2024","unstructured":"Higgins JP, Morgan RL, Rooney AA, et al.. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024, 186:108602. 10.1016\/j.envint.2024.108602","journal-title":"Environ Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.8605","article-title":"A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies","volume":"24","author":"Daniel S","year":"2025","unstructured":"Daniel S, Waggett S, Lyles E, et al.. A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies. J Drugs Dermatol. 2025, 24:413-5. 10.36849\/JDD.8605","journal-title":"J Drugs Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02883-1","article-title":"Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"30","author":"Wadden TA","year":"2024","unstructured":"Wadden TA, Chao AM, Machineni S, et al.. Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2024, 30:1784. 10.1038\/s41591-024-02883-1","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.10.076","article-title":"Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years","volume":"181","author":"Danne T","year":"2017","unstructured":"Danne T, Biester T, Kapitzke K, et al.. Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years. J Pediatr. 2017, 181:146-153.e3. 10.1016\/j.jpeds.2016.10.076","journal-title":"J Pediatr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07613-w","article-title":"Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study","author":"Nakhla M","year":"2024","unstructured":"Nakhla M, Nair A, Balani P, et al.. Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study. Cardiovasc Drugs Ther. 2024, 10.1007\/s10557-024-07613-w","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop F","year":"2023","unstructured":"Knop F, Aroda V, Vale R, et al.. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 402:705-19. 10.1016\/S0140-6736(23)01185-6","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49864","article-title":"Assessing the impact of alopecia on quality of life, depression, and self-esteem in Saudi Arabia","volume":"15","author":"Alzoabi NM","year":"2023","unstructured":"Alzoabi NM, Alsharif HM Sr, Alawami AM, Habarah HH, Alhawaj HA, Bin Rubaian N, Alqahtani JM. Assessing the impact of alopecia on quality of life, depression, and self-esteem in Saudi Arabia. Cureus. 2023, 15:e49864. 10.7759\/cureus.49864","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian D","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, et al.. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025, 122:344-67. 10.1016\/j.ajcnut.2025.04.023","journal-title":"Am J Clin Nutr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20512","article-title":"Exploring the hair loss risk in glucagon-like peptide-1 agonists: emerging concerns and clinical implications","volume":"39","author":"Buontempo MG","year":"2025","unstructured":"Buontempo MG, Santos BT. Exploring the hair loss risk in glucagon-like peptide-1 agonists: emerging concerns and clinical implications. J Eur Acad Dermatol Venereol. 2025, 39:263-4. 10.1111\/jdv.20512","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04293-w","article-title":"GLP-1RA and the possible skin aging","author":"Paschou IA","year":"2025","unstructured":"Paschou IA, Sali E, Paschou SA, et al.. GLP-1RA and the possible skin aging. Endocrine. 2025, 10.1007\/s12020-025-04293-w","journal-title":"Endocrine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjae132","article-title":"Decoding the implications of glucagon-like peptide-1 receptor agonists on accelerated facial and skin aging","volume":"44","author":"Ridha Z","year":"2024","unstructured":"Ridha Z, Fabi SG, Zubar R, Dayan SH. Decoding the implications of glucagon-like peptide-1 receptor agonists on accelerated facial and skin aging. Aesthet Surg J. 2024, 44:NP809-18. 10.1093\/asj\/sjae132","journal-title":"Aesthet Surg J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17246","article-title":"GLP-1 agonists and hair loss: a call for further investigation","volume":"63","author":"Desai DD","year":"2024","unstructured":"Desai DD, Sikora M, Nohria A, Bordone L, Caplan AS, Shapiro J, Lo Sicco KI. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024, 63:1128-30. 10.1111\/ijd.17246","journal-title":"Int J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5021\/ad.24.043","article-title":"Telogen effluvium associated with weight loss: a single center retrospective study","volume":"36","author":"Kang DH","year":"2024","unstructured":"Kang DH, Kwon SH, Sim WY, Lew BL. Telogen effluvium associated with weight loss: a single center retrospective study. Ann Dermatol. 2024, 36:384-8. 10.5021\/ad.24.043","journal-title":"Ann Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389299-alopecia-as-an-emerging-adverse-effect-associated-with-glucagon-like-peptide-1-glp-1-receptor-agonists-for-weight-loss-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T21:55:05Z","timestamp":1755122105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389299-alopecia-as-an-emerging-adverse-effect-associated-with-glucagon-like-peptide-1-glp-1-receptor-agonists-for-weight-loss-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.90021","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}